Please assess the completion status of the following clinical trial:

Trial Title: Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Undergone elective total hip or knee replacement surgery~* Received postoperative venous blood clot prevention therapy within 24 hours of the surgery~* Currently prescribed enoxaparin 30mg subcutaneous (SQ) twice a day or 40mg SQ daily for venous blood clotting prevention with an expected duration of continued prevention therapy of at least 3 days after admission to a subacute unit~* Discharged from the hospital to a subacute unit (including skilled nursing facilities and rehabilitation units) and committed to remaining in the unit for the duration of the Pharmacodynamic blood sampling period of the study~Exclusion Criteria:~* Platelet count \<90,000/µL based on screening laboratory assessments~* active internal bleeding or high risk of bleeding~* history of, or condition associated with, increased bleeding risk including~* planned invasive procedure with potential for uncontrolled bleeding, including major surgery~* sustained uncontrolled high blood pressure, defined as systolic blood pressure =180 mmHg or diastolic blood pressure =100 mmHg~* clinically significant kidney disease and/or impaired kidney function~* clinically significant liver disease~* anemia~* known allergies, hypersensitivity, or intolerance to rivaroxaban~* indication for anticoagulant (blood thinning) therapy for a condition other than blood clot prevention~* anticipated need for treatment with a prescription or nonprescription non-steroidal anti-inflammatory drugs (NSAIDs)~* any patient who has taken more than one or two doses of aspirin (\>100 mg/dose) in the week prior to enrollment will not be allowed to participate~* Drug addiction or alcohol abuse within 3 years prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).